UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 20,979 Shares of ICU Medical, Inc. $ICUI

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its stake in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 26.4% during the second quarter, HoldingsChannel.com reports. The fund owned 58,442 shares of the medical instruments supplier’s stock after selling 20,979 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in ICU Medical were worth $8,568,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of ICUI. Public Employees Retirement System of Ohio bought a new position in ICU Medical in the second quarter worth approximately $51,000. Corient Private Wealth LP bought a new stake in ICU Medical during the 2nd quarter valued at $985,000. Bank of America Corp DE purchased a new stake in shares of ICU Medical in the 2nd quarter worth $54,059,000. Man Group plc purchased a new stake in shares of ICU Medical in the 2nd quarter worth $595,000. Finally, Jupiter Topco LLC bought a new position in shares of ICU Medical during the 2nd quarter worth $407,786,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical Price Performance

Shares of NASDAQ ICUI opened at $167.58 on Tuesday. ICU Medical, Inc. has a 12-month low of $112.50 and a 12-month high of $192.85. The stock’s fifty day simple moving average is $167.74 and its two-hundred day simple moving average is $144.99. The stock has a market capitalization of $4.19 billion, a PE ratio of 142.02, a price-to-earnings-growth ratio of 2.12 and a beta of 0.75. The company has a current ratio of 2.43, a quick ratio of 1.21 and a debt-to-equity ratio of 0.56.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $2.37 EPS for the quarter, topping the consensus estimate of $1.91 by $0.46. The firm had revenue of $547.88 million during the quarter, compared to analyst estimates of $533.44 million. ICU Medical had a return on equity of 7.91% and a net margin of 1.39%.The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the company posted $2.10 EPS. ICU Medical has set its FY 2026 guidance at 8.600-9.000 EPS. As a group, analysts expect that ICU Medical, Inc. will post 7.19 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Ben Sousa sold 2,250 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $178.32, for a total value of $401,220.00. Following the sale, the insider directly owned 3,076 shares in the company, valued at approximately $548,512.32. This trade represents a 42.25% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Daniel Woolson sold 5,417 shares of ICU Medical stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $181.33, for a total transaction of $982,264.61. Following the completion of the transaction, the vice president directly owned 17,062 shares in the company, valued at approximately $3,093,852.46. The trade was a 24.10% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 21,830 shares of company stock valued at $3,905,003 in the last three months. 2.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on ICUI shares. BTIG Research raised their price target on ICU Medical from $170.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Zacks Research lowered shares of ICU Medical from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Sanford C. Bernstein cut shares of ICU Medical to a “market perform” rating in a report on Monday, June 15th. KeyCorp raised their target price on shares of ICU Medical from $164.00 to $182.00 and gave the company an “overweight” rating in a research report on Tuesday, July 21st. Finally, Raymond James Financial restated a “strong-buy” rating and issued a $200.00 price target on shares of ICU Medical in a report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, ICU Medical has a consensus rating of “Moderate Buy” and an average target price of $192.80.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.